Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
James Burton, DM, FRCP
Ellie Kelepouris, MD, FACP, FAHA
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
Patrick Rossignol, MD, PhD
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Javed Butler, MD
The Critical Interplay: CKD, HF, and HyperkaleAmia
Treatment Revolution in IgA Nephropathy
Shikha Wadhwani, MD
Dana Rizk, MD
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
Sydney Tang, MBBS, MD
Incorporating Targeted Therapies in Treatment Planning for AAV
David Jayne, MD
Bernhard Hellmich, MD
Can We Do Better in IgAN?
Annette Bruchfeld, MD, PhD
KALMing the Itch: Improving QoL in Patients with CKD-aP
Joel Topf, MD
Kieran McCafferty, MD
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
Donald E. Kohan, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.